Tesa
A growth hormone releasing peptide studied for GH secretagogue activity. Tesa supports the hypothalamic-pituitary axis in growth hormone research protocols.
Compound Profile
Pharmaceutical Data Sheet
Mechanism of Action
How Tesa Works
Tesamorelin is a synthetic 44-amino acid polypeptide analog of human growth hormone-releasing hormone (GHRH) with enhanced N-terminal stability. It binds GHRH receptors on anterior pituitary somatotrophs to stimulate endogenous pulsatile GH secretion and downstream IGF-1 production — driving lipolysis, visceral fat reduction, and improved body composition while preserving physiological GH feedback regulation.
- Binds GHRH-R on anterior pituitary somatotrophs
- Activates Gs-cAMP-PKA signaling cascade
- Augments both basal and pulsatile GH release
- IGF-1 elevation of ~181 µg/L in healthy men (P<0.0001)
- Drives visceral adipose tissue lipolysis
- Increases skeletal muscle area and density (Hounsfield units)
- Selective reduction of visceral adipose tissue sustained 52 weeks
- Preserves subcutaneous adipose tissue
- Reduces hepatic fat by ~40% relative to placebo
Tesamorelin binds GHRH receptors on pituitary somatotrophs, activating Gs-cAMP-PKA signaling that stimulates GH gene transcription and pulsatile GH release. Once-daily treatment augments both basal and pulsatile GH secretion, elevating IGF-1 by ~181 µg/L (P<0.0001 in healthy men). This drives selective lipolysis in visceral adipose depots and improves muscle density.
Falutz J et al., J Clin Endocrinol Metab (2010): Pooled Phase 3 analysis of tesamorelin in HIV lipodystrophy.
Preclinical Findings
Research Models
Clinical Data
Pooled Phase 3: Sustained Visceral Fat Reduction Over 52 Weeks
A pooled analysis of two Phase 3 trials (n=806, 2:1 tesamorelin 2mg vs. placebo) demonstrated sustained visceral adipose tissue reduction maintained for up to 52 weeks. Exploratory analyses showed increased skeletal muscle density (1.56–4.86 Hounsfield units, all P<0.005), improved lipid profiles, ~40% relative hepatic fat reduction, and improved body image scores (belly appearance distress P=0.002).
Falutz J et al., J Clin Endocrinol Metab (2010); Stanley TL et al., J Infect Dis (2019).
Pooled Phase 3 RCTs, n=806 (2:1 randomization); 52-week treatment
Research Outcomes
Key Research Success Metrics
Safety Profile
Research Safety Notes
- Overall well tolerated without clinically meaningful changes in glucose parameters in pooled Phase 3
- No significant impact on diabetes control vs. placebo in 12-week T2D RCT (n=53)
- Injection site reactions (erythema, pruritus) are the most common local AEs
- Arthralgia and peripheral edema observed — consistent with GH-class elevation
- No de novo liver enzyme elevations; some studies showed decreases in pre-existing ALT levels
Tesa / Tesamorelin clinical data references the FDA-approved Egrifta for HIV-associated lipodystrophy. Research compound is for laboratory use only.
About Tesa
A growth hormone releasing peptide studied for GH secretagogue activity. Tesa supports the hypothalamic-pituitary axis in growth hormone research protocols.
All EVO Labs Research compounds are manufactured to research-grade standards and independently tested by Janoshik Analytical (Prague, est. 2013). The Certificate of Analysis for this compound includes full HPLC chromatography data, mass spectrometry confirmation, net purity percentage, and net content verification.
Research Use Only
This product is strictly for in vitro research and laboratory use only. Not for human or veterinary consumption. By purchasing, you confirm use in a controlled research setting.
